ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms…
Read moreADDvise Group is an expanding group that offers total solutions in the form of products and services to healthcare and research facilities through its subsidiaries within the business units Lab and Healthcare.
Expanding and developing ADDvise and our subsidiaries today feels more important than ever. We strive to extend, improve, and save people’s lives by developing and providing products and services for healthcare and research segments.
ADDvise Group AB (publ) (the "Company") today announces the successful completion of the written procedure that was initiated on 16 December 2021 (the "Written Procedure") in relation to the Company's outstanding up to SEK 500,000,000 senior secured bonds with ISIN SE0015222088 (the "Bonds"), that sought approval from bondholders ("Bondholders") for certain amendments to the terms…
Read moreThe board of directors of ADDvise Group AB has today been informed that one of its major shareholders, Per Åhlgren through GoMobile nu Aktiebolag, has issued call options in ADDvise Group AB to board members, senior executives and certain other employees in ADDvise Group. In total, 3,696,666 call options have been issued to eleven persons.…
Read moreADDvise Group AB’s subsidiary MRC Systems FZE has received an order from Design Infinity LCC, a Dubai based pharmaceutical industry engineering, interior design and fit out contractor. The order is worth approximately USD 1.1 million and involves design, supply, and installation of a 1000 sqm cleanroom facility for pharmaceutical production by the Himalaya Drug Company…
Read moreADDvise Group has applied to trade on Nasdaq First North Premier and has today received an approval. ADDvise Group changes its listing on 23 December 2021. Nasdaq First North Premier gives companies the opportunity to prepare for listing on the Nasdaq Main Market by setting higher requirements for information disclosure, corporate governance and financial reporting.…
Read moreADDvise Interim report Q3 2021 with comments from CEO Rikard Akhtarzand. Revenue growth of 39 percent in the third quarter, of which 12 percent was organically driven. Adjusted EBITDA came in at SEK 14.5 million an increase from SEK 5.5 million reaching an adjusted EBITDA margin of 13.4% vs 7.0% last year. Pro forma including signed letters of intent, the annual net sales of ADDvise Group is SEK 664 million with an EBITDA of SEK 111 million.
For more presentations please visit our YouTube channel.
Together we become stronger describes ADDvise leadership strategy. They work guiding and supportive. We have gained access to support functions we did not have in the business before. This has enabled us to easily develop the business and streamline many of our processes and working methods, Jonny Knekthage, CEO Tillquist.
ADDvise delivers equipment and services to healthcare and research units worldwide. The global market for medical technology is growing and is expected to continue to grow in the upcoming years.
ADDvise Group’s two business units Lab and Healthcare are part of the organizational facilitation of the stated acquisition strategy. Together, the business areas create a complete offer for our customers.
Here you will find financial information so that you as a shareholder, analyst or investor can be up to date. Financial reports, press releases and other company information.
Subscribe to our press releases and receive the information directly in the email.
